Connor, Clark & Lunn Investment Management Ltd. Arrowhead Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$28.9 Billion
Q3 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 124,529 shares of ARWR stock, worth $5.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

124,529

Holding current value

$5.14 Million

% of portfolio

0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$14.71 - $34.49 $1.83 Million - $4.3 Million	124,529 New	124,529 $4.3 Million
Q4 2022 Feb 10, 2023	SELL	$28.0 - $40.56 $826,084 - $1.2 Million	-29,503 Reduced 62.98%	17,340 $703,000
Q3 2022 Nov 10, 2022	SELL	$29.63 - $48.31 $1.18 Million - $1.93 Million	-39,950 Reduced 46.03%	46,843 $1.55 Million
Q2 2022 Aug 05, 2022	BUY	$27.79 - $50.61 $564,665 - $1.03 Million	20,319 Added 30.57%	86,793 $3.06 Million
Q1 2022 May 12, 2022	BUY	$39.62 - $69.97 $1.37 Million - $2.42 Million	34,596 Added 108.53%	66,474 $3.06 Million
Q4 2021 Feb 10, 2022	SELL	$58.09 - $82.51 $2 Million - $2.84 Million	-34,465 Reduced 51.95%	31,878 $2.11 Million
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $1.83 Million - $2.67 Million	31,373 Added 89.71%	66,343 $4.14 Million
Q2 2021 Aug 12, 2021	BUY	$62.15 - $90.32 $2.17 Million - $3.16 Million	34,970 New	34,970 $2.9 Million
Q3 2017 Nov 14, 2017	SELL	$1.69 - $4.33 $165,408 - $423,798	-97,875 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	97,875	97,875 $159,000

Others Institutions Holding ARWR

# of Institutions

340

Shares Held

101M

Call Options Held

979K

Put Options Held

496K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $4.37B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Arrowhead Pharmaceuticals, Inc. Transaction History